Choudhary Alok

Dr. Choudhary Alok

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2021 in Nature Immunology
Verified
Journal Article
Open access
PDF file
EIEdward B. Irvine
Edward B. Irvine
AOAnthony O’nEil
Anthony O’nEil
PDPatricia A. Darrah
Patricia A. Darrah
SSSally Shin
Sally Shin
CAChoudhary Alok
Choudhary Alok
GAGalit Alter
Galit Alter
Development of an effective tuberculosis (TB) vaccine has suffered from an incomplete understanding of the correlates of protection againstMycobacterium tuberculosis(Mtb). Intravenous (i.v.) vaccination with Bacille Calmette–Guérin (BCG) provides nearly complete protection against TB in rhesus macaques, but the antibody response it elicits remains incompletely defined. Here we show that i.v. BCG drives superior antibody responses in the plasma and the lungs of rhesus macaques compared to traditional intradermal BCG administration. While i.v. BCG broadly expands antibody titers and functions, IgM titers in the plasma and lungs of immunized macaques are among the strongest markers of reduced bacterial burden. IgM was also enriched in macaques that received protective vaccination with an attenuated strain ofMtb. Finally, anMtb-specific IgM monoclonal antibody reducedMtbsurvival in vitro. Collectively, these data highlight the potential importance of IgM responses as a marker and mediator of protection against TB.

1 December 2018 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
GSGeorge B. Sigal
George B. Sigal
APAbraham Pinter
Abraham Pinter
TLTodd L. Lowary
Todd L. Lowary
MKMasanori Kawasaki
Masanori Kawasaki
ALAndra Li
Andra Li
TBTobias Broger
Tobias Broger
The only currently commercialized point-of-care assay for tuberculosis (TB) that measures lipoarabinomannan (LAM) in urine (Alere LF-LAM) has insufficient sensitivity. We evaluated the potential of 100 novel monoclonal antibody pairs targeting a variety of LAM epitopes on a sensitive electrochemiluminescence platform to improve the diagnostic accuracy.

1 May 2018 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
CAChoudhary Alok
Choudhary Alok
DPDeendayal Patel
Deendayal Patel
WHWilliam Honnen
William Honnen
ZLZhong Lai
Zhong Lai
RPRaja Sekhar Prattipati
Raja Sekhar Prattipati
APAbraham Pinter
Abraham Pinter
Lipoarabinomannan (LAM), the major antigenic glycolipid of Mycobacterium tuberculosis, is an important immunodiagnostic target for detecting tuberculosis (TB) infection in HIV-1–coinfected patients, and is believed to mediate a number of functions that promote infection and disease development. To probe the human humoral response against LAM during TB infection, several novel LAM-specific human mAbs were molecularly cloned from memory B cells isolated from infected patients and grown in vitro. The fine epitope specificities of these Abs, along with those of a panel of previously described murine and phage-derived LAM-specific mAbs, were mapped using binding assays against LAM Ags from several mycobacterial species and a panel of synthetic glycans and glycoconjugates that represented diverse carbohydrate structures present in LAM. Multiple reactivity patterns were seen that differed in their specificity for LAM from different species, as well as in their dependence on arabinofuranoside branching and nature of capping at the nonreducing termini. Competition studies with mAbs and soluble glycans further defined these epitope specificities and guided the design of highly sensitive immunodetection assays capable of detecting LAM in urine of TB patients, even in the absence of HIV-1 coinfection. These results highlighted the complexity of the antigenic structure of LAM and the diversity of the natural Ab response against this target. The information and novel reagents described in this study will allow further optimization of diagnostic assays for LAM and may facilitate the development of potential immunotherapeutic approaches to inhibit the functional activities of specific structural motifs in LAM.


24 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
FFortunato Ferrara
Fortunato Ferrara
MEM. Frank Erasmus
M. Frank Erasmus
SDSara D’aNgelo
Sara D’aNgelo
CLCamila Leal-Lopes
Camila Leal-Lopes
ATAndré A. Teixeira
André A. Teixeira
ABAndrew Bradbury
Andrew Bradbury
As a result of the SARS-CoV-2 pandemic numerous scientific groups have generated antibodies against a single target: the CoV-2 spike antigen. This has provided an unprecedented opportunity to compare the efficacy of different methods and the specificities and qualities of the antibodies generated by those methods. Generally, the most potent neutralizing antibodies have been generated from convalescent patients and immunized animals, with non-immune phage libraries usually yielding significantly less potent antibodies. Here, we show that it is possible to generate ultra-potent (IC50 < 2 ng/ml) human neutralizing antibodies directly from a unique semisynthetic naïve antibody library format with affinities, developability properties and neutralization activities comparable to the best from hyperimmune sources. This demonstrates that appropriately designed and constructed naïve antibody libraries can effectively compete with immunization to directly provide therapeutic antibodies against a viral pathogen, without the need for immune sources or downstream optimization.

1 May 2013 in Virology
Verified
Journal Article
Closed access
RARaiees Andrabi
Raiees Andrabi
CWConstance Williams
Constance Williams
XWXiao-Hong Wang
Xiao-Hong Wang
LLLiuzhe Li
Liuzhe Li
CAChoudhary Alok
Choudhary Alok
MGMiroslaw K. Gorny
Miroslaw K. Gorny